Explanipedia

Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans Open

Uğur Şahin, Alexander Muik, Isabel Vogler, Evelyna Derhovanessian, Lena M. Kranz , et al. · 2025

CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection Open

Curtis J. Donskey, Erik R. Dubberke, Nicola P. Klein, Elizabeth Liles, Katarzyna Szymkowiak , et al. · 2024

Background Clostridioides difficile infection (CDI) causes substantial mortality and healthcare burden. We assessed the detoxified toxin-A/B PF-06425090 vaccine for primary CDI prevention. Methods This phase 3 observer-blinded study random…

Potential for Maternally Administered Vaccine for Infant Group B Streptococcus Open

Shabir A. Madhi, Annaliesa S. Anderson, Judith Absalon, David Radley, Raphael Simon , et al. · 2023

GBS6 elicited anti-CPS antibodies against group B streptococcus in pregnant women that were transferred to infants at levels associated with a reduced risk of invasive group B streptococcal disease. (Funded by Pfizer and the Bill and Melin…

Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical Trial Open

Hamid Hassanzadeh, James Baber, Elizabeth Begier, David C. Noriega, Hiroaki Konishi , et al. · 2023

Background Staphylococcus aureus is a global pathogen that is frequently responsible for healthcare-associated infections, including surgical site infections (SSIs). Current infection prevention and control approaches may be limited, with …

Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age Open

Flor M. Muñoz, Lawrence Sher, Charu Sabharwal, Alejandra Gurtman, Xia Xu , et al. · 2023

A three-dose primary series of 3-μg BNT162b2 was safe, immunogenic, and efficacious in children 6 months to 4 years of age. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04816643.).

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years Open

Patricia L. Winokur, Juleen Gayed, David Fitz-Patrick, Stephen J. Thomas, Oyeniyi Diya , et al. · 2023

The candidate monovalent or bivalent omicron BA.1-adapted vaccines had a safety profile similar to that of BNT162b2 (30 μg), induced substantial neutralizing responses against ancestral and omicron BA.1 strains, and, to a lesser extent, ne…

Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old Open

Robert W. Frenck, Nicola P. Klein, Nicholas Kitchin, Alejandra Gurtman, Judith Absalon , et al. · 2023

What is this summary about? This is a summary of an article about part of a clinical study for the BNT162b2 COVID-19 vaccine, also called the Pfizer-BioNTech vaccine. The article was published in the New England Journal of Medicine in May …

2134. A Phase 2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Booster Dose of a Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine (GBS6) Open

Babalwa Jongihlati, Nathan Segall, S. Block, James T. Peterson, Judith Absalon , et al. · 2022

Background Group B streptococcus (GBS) is a leading cause of invasive bacterial infections in young infants and pregnant women. Pfizer is developing a hexavalent GBS vaccine (GBS6) as a maternal vaccine to prevent invasive GBS disease due …

Plain Language Summary of Pfizer-BioNTech BNT162b2 COVID-19 Vaccine Safety in Participants at Least 16 Years Old and Protection Against COVID-19 in Participants at Least 12 Years Old Open

Stephen J. Thomas, Edson Duarte Moreira, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman , et al. · 2022

What is this summary about? This is a summary of an article about part of a clinical study for the BNT162b2 COVID-19 vaccine, also called the Pfizer-BioNTech vaccine. The article was published in the New England Journal of Medicine in Sept…

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease Open

Charu Sabharwal, Vani Sundaraiyer, Yahong Peng, Lisa Moyer, Todd Belanger , et al. · 2022

NCT03760146, NCT03828617.

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection Open

Chaitanya Kurhade, Jing Zou, Hongjie Xia, Mingru Liu, Qi Yang , et al. · 2022

Distinct SARS-CoV-2 Omicron sublineages have evolved showing increased fitness and immune evasion than the original Omicron variant BA.1. Here, we report the neutralization activity of sera from BNT162b2 vaccinated individuals or unimmuniz…

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine Open

Chaitanya Kurhade, Jing Zou, Hongjie Xia, Hui Cai, Qi Yang , et al. · 2022

The newly emerged Omicron SARS-CoV-2 has several distinct sublineages including BA.1, BA.2, and BA.3. BA.1 accounts for the initial surge and is being replaced by BA.2, whereas BA.3 is at a low prevalence at this time. Here we report the n…

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by 3 doses of BNT162b2 vaccine or BA.1 infection Open

Chaitanya Kurhade, Jing Zou, Hongjie Xia, Mingru Liu, Qi Yang , et al. · 2022

Distinct SARS-CoV-2 Omicron sublineages have evolved showing increased fitness and immune evasion than the original Omicron variant BA.1. Here we report the neutralization activity of sera from BNT162b2 vaccinated individuals or unimmunize…

Horizontal Transmission of Cytomegalovirus in a Rhesus Model Despite High-Level, Vaccine-Elicited Neutralizing Antibody and T-Cell Responses Open

Julia Li, Sabine Wellnitz, S Xiaoyuan, Yujuan Yue, Kimberli A. Schmidt , et al. · 2022

The development of a vaccine to prevent congenital human cytomegalovirus (HCMV) disease is a public health priority. We tested rhesus CMV (RhCMV) prototypes of HCMV vaccine candidates in a seronegative macaque oral challenge model. Immunog…

BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants Open

Jianying Liu, Yang Liu, Hongjie Xia, Jing Zou, Scott C. Weaver , et al. · 2022

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2 Open

Hongjie Xia, Jing Zou, Chaitanya Kurhade, Hui Cai, Qi Yang , et al. · 2022

Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches Open

Judith Absalon, Raphael Simon, David Radley, Peter C. Giardina, Kenneth Koury , et al. · 2022

Group B streptococcus (Streptococcus agalactiae, GBS) is an important cause of life-threatening disease in newborns. Pregnant women colonized with GBS can transmit the bacteria to the developing fetus, as well as to their neonates d…

Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccine Open

Hongjie Xia, Jing Zou, Chaitanya Kurhade, Hui Cai, Qi Yang , et al. · 2022

We report the antibody neutralization against Omicron SARS-CoV-2 after 2 and 3 doses of BNT162b2 mRNA vaccine. Vaccinated individuals were serially tested for their neutralization against wild-type SARS-CoV-2 (strain USA-WA1/2020) and an e…

Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity Open

Kathy Fernando, Sandeep Menon, Kathrin U. Jansen, Prakash S. Naik, Gianluca Nucci , et al. · 2021

BNT162b2-Elicited Neutralization of Delta Plus, Lambda, and Other Variants Open

Jianying Liu, Yang Liu, Hongjie Xia, Jing Zou, Scott C. Weaver , et al. · 2021

BNT162b2-elicited human sera are known to neutralize the currently dominant Delta SARS-CoV-2 variant. Here, we report the ability of 20 human sera, drawn 2 or 4 weeks after two doses of BNT162b2, to neutralize USA-WA1/2020 SARS-CoV-2 beari…

P232 Antimicrobial Resistance of Neisseria gonorrhoeae in Germany 2016–2020, results from the Gonococcal Resistance Network (GORENET) Open

Regina Selb, Kathrin U. Jansen, P Kreher, Gabriele Zuelsdorf, Eva Guhl , et al. · 2021

Background In Germany, Neisseria gonorrhoeae (NG) infections are not reportable and limited data on epidemiology and antimicrobial resistance (AMR) are available. Within the Gonococcal Resistance Network (GORENET) we monitor the NG-AMR in …

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants Open

Jianying Liu, Yang Liu, Hongjie Xia, Jing Zou, Scott C. Weaver , et al. · 2021

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents Open

Robert W. Frenck, Nicola P. Klein, Nicholas Kitchin, Alejandra Gurtman, Judith Absalon , et al. · 2021

The BNT162b2 vaccine in 12-to-15-year-old recipients had a favorable safety profile, produced a greater immune response than in young adults, and was highly effective against Covid-19. (Funded by BioNTech and Pfizer; C4591001 ClinicalTrial…

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans Open

Uğur Şahin, Alexander Muik, Isabel Vogler, Evelyna Derhovanessian, Lena M. Kranz , et al. · 2021

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants Open

Yang Liu, Jianying Liu, Hongjie Xia, Xianwen Zhang, Jing Zou , et al. · 2021

BNT162b2 Vaccine and Emerging SARS-CoV-2 Variants A total of 20 serum samples from 15 persons who received the BNT162b2 vaccine showed strong neutralization activity against recombinant viruses eng...

Neutralizing Activity of BNT162b2-Elicited Serum Open

Yang Liu, Jianying Liu, Hongjie Xia, Xianwen Zhang, Camila R. Fontes-Garfias , et al. · 2021

Variant SARS-CoV-2 and BNT162b2 Vaccine How well do serum samples obtained from persons injected with the BNT162b2 vaccine neutralize the P.1, B.1.1.7, and B.1.135 lineages of SARS-CoV-2, first ide...

Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses Open

Uğur Şahin, Alexander Muik, Evelyna Derhovanessian, Isabel Vogler, Lena M. Kranz , et al. · 2021

Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults Open

Mark J. Mulligan, Kirsten E. Lyke, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman , et al. · 2021

Performance of a Four-Antigen Staphylococcus aureus Vaccine in Preclinical Models of Invasive S. aureus Disease Open

Ingrid L. Scully, Yekaterina Timofeyeva, Arthur Illenberger, Peimin Lu, Paul Liberator , et al. · 2021

A Staphylococcus aureus four-antigen vaccine (SA4Ag) was designed for the prevention of invasive disease in surgical patients. The vaccine is composed of capsular polysaccharide type 5 and type 8 CRM197 conjugates, a clumping factor A muta…

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans Open

Uğur Şahin, Alexander Muik, Isabel Vogler, Evelyna Derhovanessian, Lena M. Kranz , et al. · 2020

BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S) stabilized in the prefusion conformation, has demonstrated…

Kathrin U. Jansen YOU? Author Swipe